11 Investor presentation First six months of 2021 Obesity care sales grew by 34% in Reported sales split in operational units Branded AOM DKK billion 2.4 42% 1 TRx count (000s) 909%0% 32 3% 1 34% 1.8 67% 24 606%0% 1.2 16 303%0% 0.6 8 0 0%0% Q1 Q 2 2 01 Q 9 3 Q4 Q1 Q 2 2 02 Q 0 3 Q4 Q 2 1 02 Q 1 2 NAO IO Market share (RHS) Growth at CER 0 Jan 2019 Jan 2020 Saxenda ® Bra Wegovy TM 1 Annual growth at CER. Each TRx data points represents one week of data EMEA: Europe, Middle East and Africa, NAO: North America operations, IO: International operations, RHS: Right hand side axis Note: Sales growth at constant exchange rates; AOM: Anti-Obesity Medications (includes Wegovy TM , Saxenda ® , Qsymia and Contrav Source: IQVIA NPA - TRx data, Weekly (ending 23 July 2021)
Download PDF file